Patient Support Programs

ALUNBRIG packaging

From finding financial assistance that may be right for you to understanding your disease, Takeda Oncology Here2Assist can provide the information you need throughout your treatment.



 Takeda Oncology Here2Assist:

  • Works with your healthcare provider and your insurance company to help get you started on your medication
  • Identifies available financial assistance that may be right for you
  • May help get you started on treatment if there is a delay in insurance coverage determination
  • Works with your pharmacy to arrange the delivery of your medication
  • Connects you to additional support services and resources
  • ARIADPASS Access

    ACCESS SUPPORT: Takeda Oncology Here2Assist Program case managers can work with you and your healthcare provider to determine your coverage options and provide additional support throughout your treatment.

  • ARIADPASS Afford

    FINANCIAL ASSISTANCE: If you need assistance affording your medication, Takeda Oncology Here2Assist can help identify financial assistance programs that may be able to help you with the cost of your treatment.

    To learn more about the Takeda Oncology Co-Pay Assistance Program, please visit www.TakedaOncologyCoPay.com or call 1-844-817-6468.

  • ARIADPASS Assure

    HELPFUL RESOURCES: Takeda Oncology Here2Assist Program case managers can provide information about additional resources that may help address day-to-day concerns associated with your treatment.


 

 

 

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.


 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More